ReWalk(US:LFWD) Globenewswireยท2025-05-15 12:00Core Insights - Lifeward Ltd. reported a revenue of $5.0 million for Q1 2025, a decrease from $5.3 million in Q1 2024, primarily due to lower sales of ReWalk Exoskeletons and MyoCycles [4][9] - The company experienced a significant increase in gross margin to 42.2% in Q1 2025, up from 26.4% in Q1 2024, attributed to a favorable mix of payors and higher sales volume of AlterG systems [5][29] - Lifeward's operating loss improved to $4.9 million in Q1 2025 from $6.5 million in Q1 2024, indicating better cost management and operational efficiency [8][9] Financial Performance - Revenue from AlterG products and services increased by 17% to $3.3 million in Q1 2025, driven by higher international demand [4] - Operating expenses decreased to $7.0 million in Q1 2025 from $7.9 million in Q1 2024, reflecting cost savings from the closure of certain facilities [6][7] - The net loss narrowed to $4.8 million, or $0.46 per share, compared to a net loss of $6.3 million, or $0.73 per share, in the prior year [9][23] Market Developments - Lifeward launched the ReWalk 7 exoskeleton in the U.S. market following FDA clearance, marking a significant product advancement [6] - The company secured its first approval for a ReWalk 7 claim from a major U.S. commercial health insurance provider, expanding its market reach beyond Medicare [6] - Lifeward established a partnership with CorLife for exclusive distribution of the ReWalk Personal Exoskeleton to individuals with workers' compensation claims, aiming for greater market penetration [6] Liquidity and Guidance - As of March 31, 2025, Lifeward had $5.7 million in unrestricted cash and cash equivalents, with no debt, indicating a stable liquidity position [10] - The company expects full-year revenue for 2025 to be in the range of $28 million to $30 million, reflecting optimistic growth prospects [11]